Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy.

Liu CC, Liu CC, Kanekiyo T, Xu H, Bu G.

Nat Rev Neurol. 2013 Feb;9(2):106-18. doi: 10.1038/nrneurol.2012.263. Epub 2013 Jan 8. Review. Erratum in: Nat Rev Neurol. 2013. doi: 10.1038/nmeurol.2013.32. Liu, Chia-Chan [corrected to Liu, Chia-Chen].

2.

[Role of apolipoprotein E in the molecular pathomechanism of Alzheimer disease].

Michikawa M.

Nihon Shinkei Seishin Yakurigaku Zasshi. 2014 Feb;34(1):5-9. Review. Japanese.

PMID:
25069266
3.

Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease.

Holtzman DM, Herz J, Bu G.

Cold Spring Harb Perspect Med. 2012 Mar;2(3):a006312. doi: 10.1101/cshperspect.a006312. Review.

4.

Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.

Lautner R, Palmqvist S, Mattsson N, Andreasson U, Wallin A, Pålsson E, Jakobsson J, Herukka SK, Owenius R, Olsson B, Hampel H, Rujescu D, Ewers M, Landén M, Minthon L, Blennow K, Zetterberg H, Hansson O; Alzheimer’s Disease Neuroimaging Initiative.

JAMA Psychiatry. 2014 Oct;71(10):1183-91. doi: 10.1001/jamapsychiatry.2014.1060.

PMID:
25162367
5.

Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid β peptide.

Hashimoto T, Serrano-Pozo A, Hori Y, Adams KW, Takeda S, Banerji AO, Mitani A, Joyner D, Thyssen DH, Bacskai BJ, Frosch MP, Spires-Jones TL, Finn MB, Holtzman DM, Hyman BT.

J Neurosci. 2012 Oct 24;32(43):15181-92. doi: 10.1523/JNEUROSCI.1542-12.2012.

6.

CSF Apo-E levels associate with cognitive decline and MRI changes.

Toledo JB, Da X, Weiner MW, Wolk DA, Xie SX, Arnold SE, Davatzikos C, Shaw LM, Trojanowski JQ; Alzheimer’s Disease Neuroimaging Initiative.

Acta Neuropathol. 2014 May;127(5):621-32. doi: 10.1007/s00401-013-1236-0. Epub 2014 Jan 3.

7.

Senile dementia associated with amyloid beta protein angiopathy and tau perivascular pathology but not neuritic plaques in patients homozygous for the APOE-epsilon4 allele.

Vidal R, Calero M, Piccardo P, Farlow MR, Unverzagt FW, Méndez E, Jiménez-Huete A, Beavis R, Gallo G, Gomez-Tortosa E, Ghiso J, Hyman BT, Frangione B, Ghetti B.

Acta Neuropathol. 2000 Jul;100(1):1-12.

PMID:
10912914
8.

Genetics and brain injury: apolipoprotein E.

Samatovicz RA.

J Head Trauma Rehabil. 2000 Jun;15(3):869-74. Review.

PMID:
10785619
9.

Apolipoprotein E in synaptic plasticity and Alzheimer's disease: potential cellular and molecular mechanisms.

Kim J, Yoon H, Basak J, Kim J.

Mol Cells. 2014 Nov;37(11):767-76. doi: 10.14348/molcells.2014.0248. Epub 2014 Oct 30. Review.

10.

Effect of apolipoprotein E genotype and diet on apolipoprotein E lipidation and amyloid peptides: randomized clinical trial.

Hanson AJ, Bayer-Carter JL, Green PS, Montine TJ, Wilkinson CW, Baker LD, Watson GS, Bonner LM, Callaghan M, Leverenz JB, Tsai E, Postupna N, Zhang J, Lampe J, Craft S.

JAMA Neurol. 2013 Aug;70(8):972-80. doi: 10.1001/jamaneurol.2013.396.

11.

The Complex Role of Apolipoprotein E in Alzheimer's Disease: an Overview and Update.

Mahoney-Sanchez L, Belaidi AA, Bush AI, Ayton S.

J Mol Neurosci. 2016 Nov;60(3):325-335. Epub 2016 Sep 19. Review.

PMID:
27647307
12.

Human apoE isoforms differentially regulate brain amyloid-β peptide clearance.

Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, Patterson BW, Fagan AM, Morris JC, Mawuenyega KG, Cruchaga C, Goate AM, Bales KR, Paul SM, Bateman RJ, Holtzman DM.

Sci Transl Med. 2011 Jun 29;3(89):89ra57. doi: 10.1126/scitranslmed.3002156.

13.

The role of apolipoprotein E in Alzheimer's disease.

Kim J, Basak JM, Holtzman DM.

Neuron. 2009 Aug 13;63(3):287-303. doi: 10.1016/j.neuron.2009.06.026. Review.

14.

Formation and function of apolipoprotein E-containing lipoproteins in the nervous system.

Vance JE, Hayashi H.

Biochim Biophys Acta. 2010 Aug;1801(8):806-18. doi: 10.1016/j.bbalip.2010.02.007. Epub 2010 Feb 17. Review.

PMID:
20170744
15.

Association of apolipoprotein E genetic variation in Alzheimer's disease in Indian population: a meta-analysis.

Agarwal R, Tripathi CB.

Am J Alzheimers Dis Other Demen. 2014 Nov;29(7):575-82. Review.

PMID:
25551132
16.

Apolipoprotein E genotype regulates amyloid-beta cytotoxicity.

Wilhelmus MM, Otte-Höller I, Davis J, Van Nostrand WE, de Waal RM, Verbeek MM.

J Neurosci. 2005 Apr 6;25(14):3621-7.

17.

Blocking the apoE/Aβ interaction ameliorates Aβ-related pathology in APOE ε2 and ε4 targeted replacement Alzheimer model mice.

Pankiewicz JE, Guridi M, Kim J, Asuni AA, Sanchez S, Sullivan PM, Holtzman DM, Sadowski MJ.

Acta Neuropathol Commun. 2014 Jun 28;2:75. doi: 10.1186/s40478-014-0075-0.

18.

Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer disease.

Tiraboschi P, Hansen LA, Masliah E, Alford M, Thal LJ, Corey-Bloom J.

Neurology. 2004 Jun 8;62(11):1977-83.

PMID:
15184600
19.

[Expression of apolipoprotein E in Alzheimer's disease and its significance].

He SR, Liu DG, Wang S, Xia YJ.

Zhonghua Bing Li Xue Za Zhi. 2005 Sep;34(9):556-60. Chinese.

PMID:
16468304
20.

Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer's disease.

Holtzman DM, Bales KR, Wu S, Bhat P, Parsadanian M, Fagan AM, Chang LK, Sun Y, Paul SM.

J Clin Invest. 1999 Mar;103(6):R15-R21.

Supplemental Content

Support Center